Cambridge, MA--(November 30, 2015) – BioPact Ventures, LLC today announced the appointment of Joe Dillon, Ph.D., as Chief Executive Officer, effective immediately. Dr. Dillon joined BioPact in June 2015 as its executive advisor and will lead the company as it advances its MGMR® medical technology. He replaces Kent Phelps, co-founder of BioPact. Mr. Phelps will continue to be involved with Bio-Pact as a consultant and as the Chief Legal Counsel.
“BioPact continues to develop and advance its MGMR®, a unique and proprietary composition of discrete carbon nanotubes with many important medical applications. We are excited about bringing Joe in to take the company to the next level," said Kurt Swogger, Manager of BioPact Ventures, LLC. "We are grateful to Kent for his leadership and success in leading the establishment of BioPact and selection of its first commercial target that of controlled release of pharmaceuticals. Joe will take it the next steps in securing the needed partners to develop specific applications that will bring MGMR® to market using his many years of experience and knowledge”.
Dr. Dillon was most recently President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 20 years of experience. He has extensive experience in global pharmaceutical and biotechnology business strategy and planning, product development, operations and strategic transactions. Prior to forming SynerPhysics and Dillon Capital Strategies, Dr. Dillon held senior positions in two pharmaceutical management consulting firms, most significantly was as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. Dr. Dillon holds a Ph.D. in Metaphysics, an M.B.A. in International Finance and a bachelors in Finance.
BioPact is a medical nano-technology development company based in Cambridge, MA. Bio-Pact’s Medical Grade Molecular Rebar (MGMR®), is a unique composition of matter derived from carbon nanotubes, which are discrete (individual), open-ended, length controlled and surface functionalized. The unique physical and chemical properties of these tubes overcome the limitations of traditional carbon nanotubes. BioPact is focused on developing and partnering MGMR® for use in drug delivery, orthotics, regenerative medicine, devices, diagnostics, bio-sensors, material optimization and a number of other medical applications addressing substantial unmet needs in patient care. Please visit us at www.bio-pact.com